Ceremuzyński L, Gebalska J, Wolk R, Makowska E
Klinika Kardiologii CMKP, Szpital Grochowski, Warszawa, Poland.
J Intern Med. 2000 Jan;247(1):78-86. doi: 10.1046/j.1365-2796.2000.00585.x.
To assess the role of electrolyte imbalance in cardiac arrhythmias associated with congestive heart failure.
Serum magnesium and potassium levels, urine magnesium excretion and the incidence of ventricular arrhythmias were assessed throughout the study. The patients who displayed complex arrhythmias after the first week of hospital medication were randomized 2:1 to double-blind magnesium supplementation or placebo.
The study was carried out in one municipal hospital, providing primary care.
A total of 588 consecutive patients were screened for eligibility (clinical heart failure >/=6 months; NYHA class II-IV; left ventricular ejection fraction </=40%; sinus rhythm; serum creatinine </=2 mg dL-1). A total of 78 patients entered and 68 patients completed the study.
Intravenous administration of magnesium (magnesium sulphate 8 g in 250 mL of 5% glucose) or placebo (250 mL of 5% glucose) over 12 h.
(i) Incidence of ventricular arrhythmias in patients with hypomagnesemia; (ii) effects of magnesium supplementation on ventricular arrhythmias.
On admission, hypomagnesemia was found in 38% and excessive magnesium loss in 72% of patients. Serum magnesium levels were lower and urine magnesium excretion was greater in patients with complex ventricular arrhythmias, both on admission and after treatment for heart failure. Intravenous administration of magnesium caused a significant decrease in the number of ventricular ectopic beats (P < 0.0001), couplets (P < 0.003) and episodes of nonsustained ventricular tachycardia (P < 0.01).
Hypomagnesemia, probably related to increased urine magnesium excretion, is an essential feature of heart failure associated with complex ventricular arrhythmias. These arrhythmias can be alleviated/abolished by magnesium supplementation.
评估电解质失衡在充血性心力衰竭相关心律失常中的作用。
在整个研究过程中评估血清镁和钾水平、尿镁排泄以及室性心律失常的发生率。在医院用药第一周后出现复杂心律失常的患者按2:1随机分为双盲补充镁组或安慰剂组。
研究在一家提供初级医疗服务的市级医院进行。
共筛查了588例连续患者的入选资格(临床心力衰竭≥6个月;纽约心脏协会II-IV级;左心室射血分数≤40%;窦性心律;血清肌酐≤2mg/dL)。共有78例患者进入研究,68例患者完成研究。
在12小时内静脉注射镁(250mL 5%葡萄糖中含硫酸镁8g)或安慰剂(250mL 5%葡萄糖)。
(i)低镁血症患者室性心律失常的发生率;(ii)补充镁对室性心律失常的影响。
入院时,38%的患者存在低镁血症,72%的患者存在镁过度流失。无论是入院时还是心力衰竭治疗后,有复杂室性心律失常的患者血清镁水平较低,尿镁排泄较高。静脉注射镁可使室性早搏数量(P<0.0001)、成对早搏(P<0.003)和非持续性室性心动过速发作次数(P<0.01)显著减少。
低镁血症可能与尿镁排泄增加有关,是与复杂室性心律失常相关的心力衰竭的一个重要特征。补充镁可缓解/消除这些心律失常。